PDCD1 and neoplasm: Trametinib and anti-PD-1 combined treatment led to a significant increase in tumor-infiltrating CD3+ T cells and CD8+ T cells whereas no differences in the frequencies of tumor-infiltrating CD4+ T cells were observed.